Protara Therapeutics Reports $17.8 Million Net Loss in Q1 2026, Increases R&D Spending

Protara Therapeutics, Inc. reported a net loss of $17.8 million for the first quarter of 2026, compared to a net loss of $11.9 million during the same period in 2025. The company's total operating expenses increased to $19.6 million, up from $14.1 million year-over-year, primarily driven by higher research and development costs associated with ongoing clinical trials for its lead product candidates, TARA-002 and IV Choline Chloride. Research and development expenses rose to $13.6 million, reflecting a $4.4 million increase from the previous year, while general and administrative expenses also saw a rise to $6.1 million, an increase of $1.1 million.

In terms of financial position, Protara's total assets decreased to $191.9 million as of March 31, 2026, down from $209.5 million at the end of 2025. The company reported cash and cash equivalents of $14.7 million, a significant decline from $49.7 million at the end of the previous fiscal year. Marketable debt securities increased slightly to $121.0 million from $105.9 million, indicating a strategic focus on maintaining liquidity through investments. The accumulated deficit grew to $320.2 million, reflecting the ongoing costs associated with its clinical development programs.

Operationally, Protara is advancing its clinical trials for TARA-002, which is being evaluated for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The company is currently conducting the ADVANCED-2 trial for NMIBC, with enrollment expected to complete in the second half of 2026. The trial has shown promising interim results, with a complete response rate of 68.0% among BCG-Unresponsive patients. Additionally, Protara is pursuing IV Choline Chloride for patients on parenteral support, with a Phase 3 trial (THRIVE-3) initiated in January 2026.

Looking ahead, Protara anticipates the need for additional capital to support its ongoing clinical trials and operational expenses. The company has indicated that its current financial resources are sufficient to meet liquidity needs for at least the next 12 months. However, it acknowledges the potential challenges in raising further capital due to market volatility and economic conditions. Protara's strategic focus remains on advancing its product candidates through clinical development while managing its financial resources effectively.